Depixus launches technology access program with first MAGNA One™ instrument placement

4th January 2024

PARIS, France – Interactomics pioneer Depixus has launched its game-changing MAGNA technology access program with the deployment of the first ‘MAGNA One’ beta prototype instrument in the laboratory of Professor Jean-François Allemand, Department of Physics at the École Normale Supérieure (ENS), Paris.

Read More

Depixus announces strategic collaboration with Daiichi Sankyo to use MAGNA™ technology to accelerate RNA-targeted drug discovery

12th December 2023

PARIS, France– Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA™ technology to accelerate the Japanese healthcare leader’s RNA-targeted drug discovery…

Read More

Depixus selected for SLAS 2024 Innovation AveNEW Award

1st November 2023

PARIS, FRANCE – Interactomics pioneer Depixus is proud to announce they have been selected for the prestigious Innovation AveNEW showcase at the Society for Laboratory Automation and Screening (SLAS) International Conference & Exhibition, to be held in Boston from 3rd-7th February 2024. Designed to highlight exciting companies providing game-changing technologies for the life sciences, the …

Read More

Depixus to showcase unique single molecule technology solving the hit-to-lead challenge in RNA-targeted drug discovery at upcoming Discovery on Target Conference

20th September 2023

PARIS–(BUSINESS WIRE)–Dr Gordon Hamilton, President & CEO of Depixus SAS, will be showcasing the company’s pioneering approach to transform RNA…

Read More